Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q4 2021 Results - Earnings Call Transcript

– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 –

Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Esperion Therapeutics Inc. ( ESPR , Financial) calls itself the "Lipid Management Company," a pharmaceutical company focused on developing and commercializing affordable, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol, or LDL-C (also known as "bad cholesterol"). The company was established by Lipitor founder Dr. Roger Newton in 2008 to develop cholesterol-lowering medicines.

Esperion Therapeutics' Future Hinges on a Clinical Trial

NEXLETOL and NEXLIZET, treatments for "bad" cholesterol, have high untapped market potential in the US.

Esperion Therapeutics - A Glimmer Of Light At The End Of The Tunnel

Esperion Therapeutics continues to report lackluster growth with their NEXLETOL and NEXLIZET products. As a result, the share price continues to hit fresh all-time-lows with little-to-no signs of a reversal. The company's transformative long-term growth plan is starting to show some success with a boost in revenue and a reduction in OpEx. The market doesn't appear to be impressed.

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

ANN ARBOR, Mich., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Time.

Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference

ANN ARBOR, Mich., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the closing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and accompanying warrants to purchase an aggregate of up to 32,142,858 shares of common stock for gross proceeds of approximately $225 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriter a 30-day option to purchase up to an additional 4,821,428 shares of its common stock and/or additional warrants to purchase up to 4,821,428 shares of its common stock, which the underwriter has partially exercised for warrants to purchase 4,821,428 shares of common stock. At closing, Esperion received net proceeds from the offering of approximately $208.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.  All of the securities sold in the offering were offered by Esperion.

Esperion Announces Closing of $225 Million Public Offering

Esperion Therapeutics Inc (NASDAQ: ESPR) priced its previously announced underwritten public offering of 32.14 million shares and short-term warrants to purchase up to 32.14 million shares at $7/share and accompanying warrant. The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire two years following the date of issuance.

Esperion Shares Fall After $225M Capital Raise Via Equity

The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) fell by over 30% pre-market today. This is why it happened.

Esperion Therapeutics (ESPR) Stock: Why The Price Substantially Dropped Today

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a combined public offering price of $7.00 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire two years following the date of issuance.

Esperion Announces Pricing of $225 Million Public Offering

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in an underwritten public offering. The Company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be offered by Esperion.

Esperion Announces Proposed Public Offering

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Why Is Esperion Therapeutics (ESPR) Down 24.5% Since Last Earnings Report?

Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately.

Implied Volatility Surging for Esperion Therapeutics (ESPR) Stock Options

- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients -

Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q3 2021 Results - Earnings Call Transcript

– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth –

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update

ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021.

Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021

ANN ARBOR, Mich., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that members of Esperion's management team will participate in the upcoming Credit Suisse 30th Annual Healthcare Conference.

Esperion to Participate in Upcoming Virtual Investor Conference

Esperion continues to struggle to get NEXLETOL and NEXLIZET off the launch pad as COVID-19 headwinds disrupt their commercial efforts. The lackluster launch and relentless cash burn has crushed the share price to all-time lows.

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Shareholders were displeased with the company's latest financial move.

Why Esperion Therapeutics Plummeted by 11% Today

The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) increased by over 6% during intraday trading today. This is why it happened.

ESPR Stock: Why It Increased Today

Editas Medicine

Marriott

Penn Entertainment

CRISPR Therapeutics

Another day of strong earnings is pushing the broad markets higher across the board.

News for Esperion Therapeutics Stock (ESPR)